Acquisitions - Narrative (Details) $ in Thousands			3 Months Ended	12 Months Ended
	Jul. 08, 2025 USD ($)	Jan. 08, 2025 USD ($) arrangement	Dec. 31, 2025 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
Call Option
Business Combination [Line Items]
Stock available for repurchase		$ 10,000
Option contract period		5 years
Redemption requirement, revenue threshold		$ 5,000
Earnout 1 | Selling, General and Administrative Expenses
Business Combination [Line Items]
Contingent consideration				$ 4,900
Earnout 1 | Research and development
Business Combination [Line Items]
Contingent consideration				5,100
Akoya Biosciences, Inc.
Business Combination [Line Items]
Estimated useful life	9 years 7 months 6 days
Contract with customer, unfavorable terms	$ 16,700		$ 14,000	14,000
Contract with customer, non-cash revenue recognized				2,700
Business combination, additional revenues				33,700
Business combination, net loss				12,000
Contingent consideration	$ 82,131
Business combination, acquisition-related cost, expense				$ 12,400	$ 1,100
Emission Inc.
Business Combination [Line Items]
Estimated useful life				14 years
Number of contingent consideration arrangements | arrangement		2
Contingent consideration		$ 6,612
Emission Inc. | Earnout 1
Business Combination [Line Items]
Additional consideration			10,000	$ 10,000
Emission Inc. | Earnout 2
Business Combination [Line Items]
Additional consideration			$ 50,000	$ 50,000
Performance period			5 years
Contingent consideration		$ 6,600